Insider Selling: Intercept Pharmaceuticals Insider Sells 2,000 Shares of Stock (ICPT)
Intercept Pharmaceuticals (NASDAQ:ICPT) Insider Luciano Adorini unloaded 2,000 shares of Intercept Pharmaceuticals stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $61.07, for a total value of $122,140.00. Following the completion of the transaction, the insider now directly owns 5,094 shares of the company’s stock, valued at approximately $311,091. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
ICPT has been the subject of a number of recent research reports. Analysts at BMO Capital Markets raised their price target on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $62.00 to $107.00 in a research note to investors on Friday. They now have an “outperform” rating on the stock. Finally, analysts at Needham & Company raised their price target on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) from $40.00 to $55.00 in a research note to investors on Tuesday, August 13th. They now have a “buy” rating on the stock.
One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $61.67.
Intercept Pharmaceuticals (NASDAQ:ICPT) traded up 13.31% during mid-day trading on Friday, hitting $63.94. The stock had a trading volume of 436,042 shares. Intercept Pharmaceuticals has a one year low of $17.96 and a one year high of $64.18. The stock’s 50-day moving average is $47. and its 200-day moving average is $40.17. The company’s market cap is $1.226 billion.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by $0.28. The company had revenue of $0.41 million for the quarter, compared to the consensus estimate of $0.40 million. Analysts expect that Intercept Pharmaceuticals will post $-2.30 EPS for the current fiscal year.
Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.